Go Pro
NYSE:COR

Cencora (COR) Stock Price, News & Analysis

Cencora logo
$330.52 -6.70 (-1.99%)
As of 09/4/2026 03:58 PM Eastern

About Cencora Stock (NYSE:COR)

Advanced

Key Stats

Today's Range
$330.20
$336.01
50-Day Range
$282.04
$336.98
52-Week Range
$244.82
$377.54
Volume
1.02 million shs
Average Volume
1.24 million shs
Market Capitalization
$63.07 billion
P/E Ratio
24.56
Dividend Yield
0.73%
Price Target
$370.85
Consensus Rating
Moderate Buy

Company Overview

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers. These services include commercialization support, market access and reimbursement consulting, patient hub and adherence programs, specialty pharmacy management, and clinical support services that help bring specialty and high-cost therapies to market and to patients efficiently.

Cencora operates across multiple geographies with a network of distribution centers, specialty pharmacies and logistics facilities that serve hospitals, health systems, retailers, independent pharmacies, physician practices and manufacturers. The company’s infrastructure and service model are geared toward handling both high-volume commodity products and complex specialty medicines, including oncology, rare disease and biologic therapies.

The company was formed through the rebranding of AmerisourceBergen in 2023 and is headquartered in Conshohocken, Pennsylvania. It is led by Steven H. Collis, who has served as chief executive officer since 2011. Cencora’s business model emphasizes integrated supply chain capabilities and services that support pharmaceutical manufacturers, payers and providers in delivering therapies to patients.

AI Generated. May Contain Errors.

Cencora Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

COR MarketRank™: 

Cencora scored higher than 98% of companies evaluated by MarketBeat, and ranked 6th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cencora has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on no strong buy ratings, 13 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    Cencora has a consensus price target of $370.85, representing about 12.2% upside from its current price of $330.52.

  • Amount of Analyst Coverage

    Cencora has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cencora's stock forecast and price target.
  • Earnings Growth

    Earnings for Cencora are expected to grow by 10.63% in the coming year, from $17.87 to $19.77 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cencora is 24.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.02.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cencora is 24.56, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.10.

  • Price to Earnings Growth Ratio

    Cencora has a PEG Ratio of 1.88. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Cencora has a P/B Ratio of 19.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cencora's valuation and earnings.
  • Percentage of Shares Shorted

    2.44% of the float of Cencora has been sold short.
  • Short Interest Ratio / Days to Cover

    Cencora has a short interest ratio ("days to cover") of 2.39, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cencora has recently decreased by 10.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cencora has a dividend yield of 0.71%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Cencora has been increasing its dividend for 15 years.

  • Dividend Coverage

    The dividend payout ratio of Cencora is 17.83%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Cencora will have a dividend payout ratio of 12.14% next year. This indicates that Cencora will be able to sustain or increase its dividend.

  • Read more about Cencora's dividend.
  • News Sentiment

    Cencora has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Cencora this week, compared to 8 articles on an average week.
  • Search Interest

    12 people have searched for COR on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.
  • MarketBeat Follows

    15 people have added Cencora to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cencora insiders have sold 2,364.28% more of their company's stock than they have bought. Specifically, they have bought $148,626.00 in company stock and sold $3,662,556.00 in company stock.

  • Percentage Held by Insiders

    0.38% of the stock of Cencora is held by insiders.

  • Percentage Held by Institutions

    97.52% of the stock of Cencora is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cencora's insider trading history.
Receive COR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

COR Stock News Headlines

How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors.tc pixel
Artisan Sold Cencora (COR) as Earnings Momentum Slowed
Cencora Inc BRDR C1CO34
Cencora (NYSE:COR) EVP Sells 11,300 Shares
Cardinal Health branded boxes on pallets sit amid automated conveyor systems in a distribution warehouse.
Cardinal Health Earnings: Can Perfection Get Priced In Twice? (COR)
Cardinal Health stock hit a new all-time high after mixed earnings, with analyst price target hikes, gene therapy logistics wins and a 29-year dividend growth streak supporting the uptrend.
See More Headlines

COR Stock Analysis - Frequently Asked Questions

Cencora's stock was trading at $338.07 at the beginning of 2026. Since then, COR stock has decreased by 2.2% and is now trading at $330.52.

Cencora, Inc. (NYSE:COR) announced its quarterly earnings data on Wednesday, August, 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. The firm's quarterly revenue was up 5.1% compared to the same quarter last year.
Read the conference call transcript
.

Cencora's board authorized a share repurchase plan on Thursday, May 21st 2026, which permits the company to buy back $2,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 3.9% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its shares are undervalued.

The following companies are subsidiaries of Cencora: Alliance Healthcare, H. D. Smith, St. Francis Group, PharMEDium Healthcare, MWI Veterinary Supply, World Courier, IntrinsiQ, and others.

Cencora's top institutional shareholders include California State Teachers Retirement System (39.05%), BlackRock Inc. (9.36%), Wellington Management Group LLP (2.39%) and Bank of America Corp DE (1.96%). Insiders that own company stock include Walgreens Boots Alliance, Inc, Steven H Collis, Robert P Mauch, Robert P Mauch, Dermot Mark Durcan, Lazarus Krikorian, Elizabeth S Campbell, Silvana Battaglia, Gina Clark, Gina Clark, Leslie E Donato, Leslie E Donato and Lauren M Tyler.
View institutional ownership trends
.

Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cencora investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Broadcom (AVGO), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

Last Earnings
8/05/2026
Record date for 8/31 Dividend
8/14/2026
Ex-Dividend for 8/31 Dividend
8/14/2026
Dividend Payable
8/31/2026
Today
9/06/2026
Wells Fargo 21st Annual Healthcare Conference
9/08/2026
Fiscal Year End
9/30/2026
Next Earnings (Estimated)
11/04/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Distributors
Current Symbol
NYSE:COR
CIK
1140859
Employees
51,000
Year Founded
2001

Price Target and Rating

High Price Target
$440.00
Low Price Target
$285.00
Potential Upside/Downside
+12.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
$13.46
Trailing P/E Ratio
24.56
Forward P/E Ratio
18.50
P/E Growth
1.88
Net Income
$1.55 billion
Net Margins
0.79%
Pretax Margin
1.08%
Return on Equity
125.45%
Return on Assets
4.18%

Debt

Debt-to-Equity Ratio
3.53
Current Ratio
0.93
Quick Ratio
0.58

Sales & Book Value

Annual Sales
$321.33 billion
Price / Sales
0.20
Cash Flow
$21.59 per share
Price / Cash Flow
15.31
Book Value
$9.01 per share
Price / Book
36.68

Miscellaneous

Outstanding Shares
190,830,000
Free Float
190,102,000
Market Cap
$63.07 billion
Optionable
Optionable
Beta
0.57

Social Links

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSE:COR) was last updated on 9/6/2026 by MarketBeat.com Staff.
From Our Partners